| 000 | 01759 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250511221133.0 | ||
| 264 | 0 | _c19910801 | |
| 008 | 199108s 0 0 eng d | ||
| 022 | _a0923-7534 | ||
| 024 | 7 |
_a10.1093/oxfordjournals.annonc.a057879 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGalligioni, E | |
| 245 | 0 | 0 |
_aNatural killer (NK) and lymphokine activated killer (LAK) cell activity in patients (PTS) treated with flavone acetic acid (FAA). _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cFeb 1991 |
||
| 300 |
_a145-50 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xpharmacokinetics |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFlavonoids _xpharmacokinetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKiller Cells, Lymphokine-Activated _ximmunology |
| 650 | 0 | 4 |
_aKiller Cells, Natural _ximmunology |
| 650 | 0 | 4 |
_aLeukocytes, Mononuclear _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aReference Values |
| 700 | 1 | _aQuaia, M | |
| 700 | 1 | _aSpada, A | |
| 700 | 1 | _aCrivellari, D | |
| 700 | 1 | _aFavaro, D | |
| 700 | 1 | _aSorio, R | |
| 700 | 1 | _aTalamini, R | |
| 700 | 1 | _aD'Incalci, M | |
| 700 | 1 | _aAllavena, P | |
| 700 | 1 | _aDamia, G | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 2 _gno. 2 _gp. 145-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/oxfordjournals.annonc.a057879 _zAvailable from publisher's website |
| 999 |
_c2060483 _d2060483 |
||